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ABSTRACT 
Objective: Rituximab (RTX) is a B cell depleting agent used to induce and maintain 
remission in patients with Granulomatosis with polyangiitis (GPA). As the development of 
hypogammaglobulinemia in GPA patients on long-term RTX has not been addressed, the aim 
of this study was to investigate changes in immunoglobulin levels and risk factors for 
hypogammaglobulinemia during long-term RTX maintenance therapy in GPA. 
Methods: Single centre cohort study of 29 GPA patients who received median total 
cumulative dose of cyclophosphamide (CYC) of 17g and were treated with RTX 2g followed 
by retreatment with either 2g once annually, 1g biannually or a combination of both. 
Immunoglobulin (Ig) levels were measured before each RTX re-treatment and 
hypogammaglobulinemia was defined as levels of total immunoglobulin < 6g/l. 
Results: During a median follow-up of 4 years, patients received a cumulative dose of 9g 
RTX. While serum immunoglobulin levels decreased during RTX maintenance, the largest 
decrease occurred after the first infusion. Baseline Ig levels and the CYC cumulative dose 
predicted Ig levels whereas the RTX cumulative dose did not. Eight patients (28%) 
discontinued RTX due to hypogammaglobulinemia. Male gender (HR=8.7 p=0.044), kidney 
involvement (HR=6.5 p=0.083) and the 1g biannually regimen (HR=8.0 p=0.024) increased 
the risk to discontinue RTX due to hypogammaglobulinemia whereas orbital-subglottic 
involvement (HR=0.23 p=0.080) decreased it.  
Conclusion: Hypogammaglobulinemia occurred in a quarter of GPA patients during RTX 
maintenance, independently of the RTX cumulative dose. Male gender, kidney involvement 
and the 1g biannually RTX regimen constitute risk factors for severe 
hypogammaglobulinemia necessitating withdrawal of RTX.  
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INTRODUCTION 
Rituximab (RTX) is a chimeric human-mouse monoclonal antibody that gives rapid sustained 
depletion of premature and mature B-cells through antibody-dependent, complement-
mediated cellular cytotoxicity and apoptosis [1]. RTX reduces auto-antibody producing 
precursor plasma cells, inhibits B cells interaction with autoreactive T cells and decreases the 
level of soluble factors secreted by B cells [1]. B cells usually return to pre-treatment level 
within twelve months after RTX [2].  
RTX is approved for the treatment of rheumatoid arthritis (RA) and ANCA-associated 
vasculitis (AAV) and used off label in a large number of autoimmune conditions [3]. In AAV, 
RTX is used both for induction [4,5] and maintenance [6-10] of remission through iterative 
RTX infusions. Relevant side effects include late onset neutropenia, hypogammaglobulinemia 
development and an increased risk for infections [11-14].  
However the long-term safety profile of RTX in AAV is not as well documented as in RA 
[13-15]. RTX is associated with a greater decrease in immunoglobulin (Ig) levels in RA 
patients treated with a cumulative dose of 5 grams or more [16] and in AAV patients 
previously treated with cyclophosphamide (CYC) [17]. In the light of its multiple immune 
modulating mechanisms, the long-term effects of RTX on natural autoantibodies production 
and T and NK cells levels are of special interest.  
To analyse the impact on Ig levels and lymphocyte subpopulations and to determine risk 
factors to hypogammaglobulinemia during long-term RTX maintenance, we investigated the 
course of these variables in 29 patients with Granulomatosis with polyangiitis (GPA) who 
received RTX 5g or more at our centre.   
 
METHODS 
Since 2001 the vasculitis disease registry (Nordnorsk Vaskulittregister) has collected 
information on disease presentation and course from patients with an established diagnosis of 
primary vasculitis followed at the University Hospital of North Norway. All patients gave 
informed written consent at registry inclusion according to the declaration of Helsinki. The 
study did not require formal ethical approval in accordance with the standards applied in 
Norway.  
This analysis concerns 29 GPA patients from that registry who were treated with RTX 
between April 2004 and September 2011. All patients satisfied the American College of 
Rheumatology 1990 classification and/or Chapel Hill consensus conference criteria. 
The patients -15 men (52%) and 14 women (48%) with a median age of 50 (9-75) years at 
RTX initiation – were mostly ANCA positive (86% PR3-ANCA, 3% MPO-ANCA and 10% 
ANCA negative) at diagnosis and had renal (59%), pulmonary (66%) and orbital-subglottic 
(62%) involvements. At RTX initiation, patients had median disease duration of 57 (22-70) 
months and they had received a median total CYC cumulative dose of 17 (0-250) g.  
 
RTX treatment was initiated as two 1-gram infusions 2 weeks apart with co-administration of 
methylprednisolone 125 mg, paracetamol 1000 mg and either cetirizine 10 mg or polaramine 
4 mg (RA protocol). Due to the observed RTX efficacy and the relapsing nature of GPA, 
RTX was then re-administered pre-emptively either as 2g infusion (1g twice during a 
fortnight) annually or as 1g infusion biannually (1g every 6 months). RTX 1g biannually 
became the preferred maintenance regimen as it was found to better sustain B cell depletion 
than the 2g annually regimen. During maintenance, 12 (41%) patients received the 1g 
biannually regimen, 6 (21%) patients received the 2g annually regimen and 11 (38%) patients 
alternated between regimens.  
 
RTX was added to other immunosuppressive drugs (ID) (other than prednisolone) in 27 
patients (93%), while 2 patients (7%) received RTX in monotherapy. Nine patients (31%) 
were given RTX in combination with a median CYC dose of 5 (2.8-6) grams. Median 
duration of combination treatment of RTX with other ID was 24 (1-54) months. The timing 
and pace of ID discontinuation was at the discretion of the treating physician, whereas the 
daily prednisolone dose was tapered from a median of 22.5 mg at baseline and discontinued in 
a protocolized manner. Patients received a median cumulative RTX dose of 9 (5-13) grams 
and were followed a median of 49 (19-88) months after RTX initiation. At last visit, 17 
patients (59%) were still treated with long-term pre-emptive RTX and almost all (except for 3 
patients) had discontinued other ID. Twelve patients (41%) had discontinued RTX mainly due 
to clinical concerns about hypogammaglobulinemia (67%) and recurrent infections (42%). 
One patient (3%) died during the study period. 
 
Fixed set of blood tests (including ANCA, Ig classes’ quantification and flow cytometric 
immunophenotyping of lymphocytes) were performed prior RTX initiation and before each 
new re-treatment until either 30th September 2011 (closing date of this study) regardless of 
ongoing therapy - or shortly before the start of intravenous immunoglobulins (IVIG) 
administration due to hypogammaglobulinemia and/or infections.  Ig levels were measured by 
nephelometry with normal ranges defined as IgG 7.0-16.0g/L, IgA 0.7-4.0g/L, IgM 0.4-
2.3g/L. Total Ig was defined as the sum of IgG, IgA and IgM serum levels. Lowest levels of 
Ig during long-term RTX maintenance – nadir Ig levels - were recorded. Decline in Ig 
between each RTX 2g increment at 2, 4, 6 and 8g of RTX were determined. 
Hypogammaglobulinemia was defined as total Ig under 6g/L. 
 
Data were analysed with SPSS version 20.0 (SPSS Ltd, Chicago IL, USA). Descriptive 
studies were first performed to assess Ig levels and lymphocytes’ subtypes for each 2g RTX 
increment. Linear regression models were afterwards used to identify factors predicting levels 
for each Ig class during RTX long-term pre-emptive maintenance; the linear regression fit was 
assessed by visual inspection of the residuals plot. Patients that discontinued due to 
hypogammaglobulinemia were compared with the remaining patients from the cohort (control 
group). Difference in immunoglobulin serum levels and their decline between groups were 
analysed using Mann-Whitney U tests. Kaplan-Meier survival curves were used to identify 
factors responsible for RTX discontinuation due to hypogammaglobulinemia. Finally, logistic 
binary regression and Cox’s proportional hazard models – unadjusted and multivariate 
analysis with backward Wald selection (variable removed if p>0.1) - were used to determine 
individual risk factors and the most important single risk factor for hypogammaglobulinemia. 
P-values <0.05 were considered significant 
 
RESULTS 
 Changes in Ig levels  
About 30% of the patients had low levels of IgG (<7 g/L) and/or IgM (<0.4 g/L) prior to RTX 
initiation. The proportion of patients with low levels IgG and/or IgM increased to about 60% 
after the administration of 2g RTX and to about 70% after 6g RTX. The proportion of patients 
with low IgA (<0.7 g/L) increased from 7% after RTX 2g to 29% after 10g RTX. None of the 
patients was hypogammaglobulinemic prior to RTX initiation, but 11% and 16% were 
hypogammaglobulinemic after respectively RTX 2g and RTX 6g (Table 1). 
Median levels of total Ig and its classes showed a continuous decrease under long-term RTX 
maintenance (Table1). However, the largest decline was seen after the first 2g of RTX with 
the decrease becoming less pronounced in the following rounds (Figure1).  In contrast, NK 
and CD4 cell counts as well as CD4/CD8 ratio increased (Table 1).  
 
Predictors of Ig levels during RTX maintenance  
Ig levels during long-term pre-emptive RTX maintenance were partly dependent of the levels 
in Ig at baseline – except for IgA (R²=0.079, p=0.076) (See supplementary Table S1, 
available at Rheumatology Online). This relation was particularly strong with IgM (R²=0.561, 
p<0.001) and to a lesser extent with IgG (R²=0.179, p=0.013).  
Male gender and older age decreased Ig levels, except for IgA. Men had 2g/L lower IgG level 
at nadir compared to women during long-term RTX maintenance. The RTX cumulative dose 
did not predict the levels of any Ig classes during long-term RTX maintenance. On the other 
hand the cumulative CYC dose significantly decreased the IgG (R²=0.107, p=0.047) and IgA 
(R²=0.133, p=0.029) levels. CD4 cell count at baseline did not predict levels of any Ig classes, 
although higher CD4 cell count at baseline seemed to protect from lower IgG levels 
(R²=0.065 p=0.098).  Variability of Ig levels during long-term RTX maintenance – 
determined by multiple linear regression models with backward selection - differed in Ig 
classes. Age, total CYC cumulative dose and baseline IgG level explained 40% of the 
variability of IgG level during RTX maintenance while male gender, total CYC cumulative 
dose and baseline IgM level explained 67% of the variability of IgM. However the total CYC 
cumulative dose was the lone predictor of IgA level, only explaining 13% of its variability. 
  
 RTX discontinuation due to hypogammaglobulinemia 
Patient characteristics 
Eight patients (28%) discontinued RTX due to hypogammaglobulinemia. They had their first 
episode of hypogammaglobulinemia a median of 63 (17-212) weeks from RTX initiation 
before they discontinued RTX after a median of 189 (100-356) weeks. 
Hypogammaglobulinemia was complicated in 6 patients: 2 patients had concomitant severe 
infections; 3 had recurrent infections and 2 had late onset neutropenia. These patients were 
mostly male, had received a higher CYC cumulative dose and received the 1g RTX 
biannually maintenance regimen (Table 2). Five patients had kidney involvement without 
orbital-subglottic involvement whereas 1 patient had orbital-subglottic involvement without 
kidney involvement. Three of these 8 patients had had a previous episode of transient 
hypogammaglobulinemia (total Ig levels ranging from 3.7 to 5.0 g/L) before RTX initiation (a 
median of 3 years from GPA diagnosis) while receiving CYC.  
In addition to the 8 patients that discontinued RTX, 5 other patients had 
hypogammaglobulinemia during RTX maintenance, without RTX being discontinued. One 
patient had 2 episodes of hypogammaglobulinemia, but none had transient 
hypogammaglobulinemia before RTX initiation. They had their first episode of 
hypogammaglobulinemia 108 (80-218) weeks from RTX initiation lasting 32 (16-156) weeks 
and they continued RTX maintenance during 291 (156-365) weeks before censoring. One 
patient did eventually discontinue during the study period after receiving a renal transplant. 
Five patients received IVIG due to hypogammaglobulinemia; four of them discontinued RTX. 
 
RTX survival time  
The mean drug survival time on RTX in our cohort was 304 weeks (95% CI 268-340 weeks). 
RTX survival time in men was almost 2 years shorter than in women (261 vs 347 weeks; 
p=0.017).  Patients with kidney involvement had shorter mean RTX survival time (275 vs 346 
weeks, Log rank p=0.047). On the other hand, patients with orbital-subglottic involvement 
had longer mean RTX survival time (334 vs 228 weeks; Log rank p=0.056). There was no 
difference in mean RTX survival time for patients with lung involvement (298 vs 312 weeks; 
Log rank p=0.696) (See supplementary Figure 1, available at Rheumatology Online).  
RTX maintenance regimens played an important role in RTX survival time: the 1g biannually 
regimen decreased significantly the mean RTX survival time compared to the 2g annually 
regimen and the combination of both regimens (Log rank p=0.027) (Figure 2).  
 
Risk factors to discontinue RTX due to hypogammaglobulinemia 
Total Ig levels in patients that discontinued RTX due to hypogammaglobulinemia had an 
early decline after the first RTX 2g but also a late decline after a RTX cumulative dose 
superior to 6g compared to the control group (Figure 3 and supplementary Table S2, available 
at Rheumatology Online). IgA levels after RTX 2g seemed to be the single most important 
risk factor to discontinue RTX due to hypogammaglobulinemia during long-term RTX 
maintenance (OR=0.01; p=0.069) – adjusted for gender after backward Wald selection (See 
supplementary Table S3, available at Rheumatology Online). 
Of interest, patients that discontinued RTX due to hypogammaglobulinemia had lower CD4 
cell count after the administration of RTX 2g (0.26 vs 0.39 x109/L p=0.075) and RTX 4g 
(0.24 vs 0.50 x109/l p=0.010) compared to the control group (See supplementary Table S2, 
available at Rheumatology Online). 
 
In unadjusted Cox’s proportional hazard regression models, male patients and those treated 
with the 1g biannually regimen were 8 times more likely to discontinue RTX during long-
term maintenance due to hypogammaglobulinemia (Table 3). A 10g increment in the CYC 
cumulative dose increased the risk to discontinue RTX due to hypogammaglobulinemia by 
14% while orbital-subglottic involvement decreased its risk by 77% (p=0.080) (Table 3). 
Male gender and the 1g biannually regimen for RTX maintenance were the single most 
independent predictors to discontinue RTX due to hypogammaglobulinemia (respectively 
HR=8.7 p=0.050 and HR=8.4 p=0.037) after backward Wald selection (Table 3). 
 
DISCUSSION 
In GPA patients treated with long-term pre-emptive RTX maintenance, our study showed that 
the largest serum Ig decline occurred after the first 2g RTX and that the RTX cumulative dose 
did not influence Ig levels whereas the cumulative CYC dose did. Male gender and the 1g 
biannually regimen were risk factors for RTX discontinuation due to 
hypogammaglobulinemia.  
 
Previous studies in AAV/GPA reported a decline in Ig levels during long-term remission 
maintenance with RTX, but studies had different maintenance strategies [8-10]. The 
proportion of patients with low IgG or IgM at baseline in our study was similar to the study 
by Smith et al [9], but started to diverge after the administration of RTX 6g as 70% of our 
patients had low IgG or IgM by then. Our study included patients treated with RTX in 
combination with other ID whereas the study of Smith et al included mostly patient treated 
with RTX monotherapy (97%) [9]. Neither this study nor the study of Venhoff et al showed 
lower Ig levels with the concomitant use of ID during RTX maintenance [17] despite the fact 
that in our study patients treated longer with concomitant ID had received a higher CYC 
cumulative dose (data not shown).  
 
Our study shows clearly that GPA patients are different from RA patients in term of 
immunoglobulin serum levels at RTX initiation and during maintenance. At baseline, 3.5% of 
the RA patients treated with RTX from the AIR registry had low IgG levels [14] compared to 
30% in our study. RA patients had a gradual incidence with low IgM levels (10% after the 
first round and 40% after the fifth RTX round) [13,18] during long-term RTX re-treatment 
while the prevalence of low IgG levels was either stable (3-6%) [13] or increased to a lesser 
extent (12% after the first round to 22% in the fifth round) [18]. CYC use prior RTX 
administration in GPA patients might explain lower IgG and IgA levels during RTX 
maintenance. A 10g CYC cumulative dose increment increased the risk to discontinue RTX 
due to hypogammaglobulinemia confirming the synergistic effect of CYC and RTX in GPA 
patients [17]. Moreover CYC induced hypogammaglobulinemia before RTX initiation could 
also increase the risk to discontinue RTX due to hypogammaglobulinemia during long-term 
maintenance.  
 
In our study, patients that discontinued RTX due to hypogammaglobulinemia had an early 
and a late decline of their total immunoglobulin levels during RTX long-term pre-emptive 
maintenance. The type of RTX maintenance regimen could explain this double-dip in Ig 
levels. The 1g biannually RTX maintenance regimen increased the risk for 
hypogammaglobulinemia compared to the 2g-annually regimen (used in RA). Thus allowing 
B cells recovery during RTX maintenance could prevent hypogammaglobulinemia. Other 
maintenance strategies allowing B cells repopulation after each re-treatment [10] or after 2 
years and a RTX cumulative dose of 6g [9] have not reported an increased risk of 
hypogammaglobulinemia while patients had an equivalent follow-up time and received the 
same RTX cumulative dose. 
 
Low levels of Ig at initiation and especially after the first RTX 2g increased the risk of 
hypogammaglobulinemia. IgA levels usually remained stable under RTX maintenance [13,19] 
and interestingly RA patients with raised IgA level had a less robust clinical response and 
earlier B cells repopulation coincident with relapse [19]. In our study, IgA levels after the first 
RTX 2g seemed to be a reliable independent marker in identifying patient at risk for 
hypogammaglobulinemia during RTX long-term pre-emptive maintenance as nadir IgA levels 
were less dependent of their baseline levels and independent of gender and age. Low IgA 
levels (<1.0g/L) could reflect a deeper B cell depletion. 
 
In our study, CD4 and NK cells levels increased while immunoglobulins decreased during 
long-term B cell depletion. Of interest, B-cell depletion by RTX at induction in non-sensitized 
patients undergoing renal transplantation increased the risk of acute cellular rejection in the 
first 3 months after transplantation [20].  These consequences of B cell depletion by RTX 
could also be explained by non-depleted B cells as they enhanced CD4 cells proliferation in 
vitro [21]. 
 
GPA patients with orbital-subglottic involvement seemed to have a reduced risk to 
discontinue RTX due to hypogammaglobulinemia, whereas GPA patients with kidney 
involvement seemed to have a higher risk. Toxic effect from aggressive immunosuppressive 
therapies and renal capillary leakage could increase the risk for hypogammaglobulinemia in 
GPA patients with kidney involvement [22]. But it is also possible that GPA patients with 
kidney involvement are generally more immunodeficient compared to patients with orbital-
subglottic involvement.  
 
Our retrospective study had some limitations mainly due to the small sample size making 
subgroups analysis prone to type II errors of not detecting differences and to wide confidence 
interval in both the logistic binary regression and Cox’s proportional hazard models analysis. 
But the longitudinal data was collected prospectively in a disease registry from a single 
tertiary centre. We also analysed patients that discontinued RTX due to 
hypogammaglobulinemia, reflecting a more severe phenotype complicated by infections. 
RTX discontinuation purely based on isolated hypogammaglobulinemia could have major 
consequences for ensuing remission maintenance therapy in GPA patients. Further studies are 
needed to determine if our findings are also valid in microscopic polyangiitis (MPA) and 
eosinophilic granulomatosis with polyangiitis (EGPA). 
 
In conclusion, long-term pre-emptive treatment with RTX 1g every six months increased the 
risk of discontinuation due to hypogammaglobulinemia in GPA patients. Male gender, kidney 
involvement, exposure with CYC and low Ig serum levels at RTX initiation were independent 
risk factors, whereas the RTX cumulative dose did not influence this risk. As 
hypogammaglobulinemia may limit the number of times anti-CD20 mediated B cell depletion 
can be carried out [3], close monitoring of immunoglobulins and lymphocytes subtypes 
during maintenance is warranted as hypogammaglobulinemia with low CD4/CD8 ratio are 
known risk factors for severe infections in AAV [23].  
 
Key messages 
• Compared to RA, rituximab maintenance in granulomatosis with polyangiitis had an 
increased risk for hypogammaglobulinemia 
• Granulomatosis with polyangiitis men with kidney involvement and prior 
cyclophosphamide exposure discontinued rituximab maintenance due to 
hypogammaglobulinemia. 
• The 1g biannually maintenance regimen in granulomatosis with polyangiitis increased 
the risk of hypogammaglobulinemia necessitating rituximab withdrawal 
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Table 1. Median serum levels of Ig (g/L) and lymphocytes types (x109/L) prior to RTX 





















No patients 29 28# 28# 25 14 7 3 29  
IgG 7.7 6.1 6.4 6.0 6.3 5.4 4.4 4.9 
% with low IgG 28 54 64 68 57 71 67 76 
IgA 1.62 1.29 1.24 1.30 1.04 1.57 2.5 1.00 
% with low IgA 0 7 7 8 14 29 33 17 
IgM 0.68 0.33 0.31 0.28 0.19 0.13 0.11 0.18 
% with low IgM 28 64 68 76 71 86 67 76 
Total Ig 10 7.9 7.9 7.5 7.9 8.1 7.1 6.3 
% with 
hypogammaglobulinemia 0 11 18 16 29 29 33 45 
B cells 0.07 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 NR 
CD4 cells 0.30 0.36 0.46 0.65 0.73 0.71 1.05 NR 
CD4/CD8 ratio 1.12 1.02 1.20 1.53 1.35 1.30 2.02 NR 
NK cells 0.14 0.17 0.24 0.26 0.31 0.33 0.29 NR 
 
CD: cluster of differentiation; Ig: immunoglobulins; No: number; NR: not reported; RTX: 
rituximab.  
# Ig results missing in 1 patient after RTX 2g and after RTX 4g. 
 
    
Table 2. Comparison between patients that discontinued RTX due to 
hypogammaglobulinemia and the rest of the cohort (control group) 
Results expressed in median (range) and percentage (number of patients) as appropriate. 
ANOVA and Fisher’s exact test were used appropriately to test for difference between 
groups. 
 







Male 88% (7) 44% (9) 0.035 
Age years 53 (23-62) 48 (9-75) 0.753 
BVAS at baseline  9.5 (4-12) 10.0 (4-21) 0.334 
Kidney involvement 88% (7) 48% (10) 0.093 
Lung involvement 75% (6) 62% (13) 0.675 
Orbital-subglottic involvement 38% (3) 71% (15) 0.197 
CYC cumulative dose g 51 (2-250) 13 (0-60) 0.037 
RTX cumulative dose g 7.0 (5-13) 9.0 (5-13) 0.074 
MTX under RTX maintenance 25% (2) 43% (9) 0.419 
AZA under RTX maintenance 25% (2) 29% (6) 1.000 
MMF under RTX maintenance 13% (1) 33% (7) 0.371 
1g biannually RTX regimen  50% (4) 38% (8) 0.683 
Both RTX regimens 50% (4) 22% (7) 0.433 
2g  annually RTX regimen 0% (0) 29% (6) 0.148 
 
AZA: azathioprine; BVAS: Birmingham vasculitis activity score; CYC: cyclophosphamide; 
MMF: mycophenolate mofetil; MTX: methotrexate; RTX: rituximab. 
Significant results (p<0.05) are highlighted in bold. 
  
Table 3. Hazard ratio to discontinue hypogammaglobulinemia during long-term pre-
emptive RTX maintenance. 
All values were determined at RTX initiation and were analysed with unadjusted and 
multivariate Cox-regression model with backward Wald selection (removal if p<0.10).  
 
 Unadjusted analysis Multivariate analysis 
 p-value HR 95% CI p-value HR 95% CI 
Male gender 0.044 8.7 1.06-72 0.050 8.7 1.00-76 
Age (10 years increments) 0.311 1.3 0.79-2.1    
Kidney involvement  0.083 6.5 0.79-54 0.141   
Lung involvement 0.698 1.4 0.28-6.8    
Orbital-subglottic involvement 0.080 0.23 0.05-1.2 0.088   
Baseline Prednisolone dose (mg) 0.958 1.00 0.95-1.1    
Concomitant CYC dose w/ RTX (g) 0.807 0.97 0.74-1.3    
Total cumulative CYC dose (10g) 0.034 1.14 1.01-1.3 0.120   
1g biannually regimen 0.024 8.0 1.3-49 0.037 8.4 1.14-63 
B cells (x109/L) 0.491 0.11 0.01-56    
CD4 cells (x109/L) 0.431 0.43 0.04-4.7    
IgG (g/L) 0.291 0.82 0.56-1.2    
IgA (g/L) 0.162 0.26 0.04-1.7    
IgM (g/L) 0.657 0.70 0.14-3.4    
Total Ig (g/L) 0.230 0.83 0.61-1.2    
CD: cluster of differentiation; CI: confidence interval; CYC: cyclophosphamide; ID: 
immunosuppressive drugs; Ig: immunoglobulin; OR: odds ratio; RTX: rituximab. w/: with 
Significant results (p<0.05) are highlighted in bold. 
 
  
Figure 1. Mean of total immunoglobulins decline after every RTX 2g increment 




Ig: immunoglobulin; RTX: rituximab. 
 









From 2 to 4g RTX
From 4 to 6g RTX






Figure 2. Kaplan-Meier analysis of the probability to discontinue rituximab due to 
hypogammaglobulinemia according to type of maintenance regimen 
 
 
Log rank, p=0.027 
Figure 3. Median total Ig levels in patients that discontinued RTX due to 














































Patients that discontinued RTX due to
hypogammaglobulinemia
